2024
Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.Peer-Reviewed Original ResearchConceptsBipolar depressionAcute seriesRisk of affective switchDiagnosis of bipolar depressionRefractory bipolar depressionAcute phaseMADRS scoreAffective switchIntranasal esketamineManic episodesBipolar disorderCohort of patientsAttending psychiatristsSource of morbidityEsketamineSample of patientsIV ketamineMaintenance treatmentDepressionClinical responseHeightened riskClinical outcomesMania/hypomaniaKetamineKetamine/esketamineBlood pressure changes during ketamine infusion for the treatment of depression
Ansari M, Pittman B, Tylee D, Ostroff R, Wilkinson S, Nikayin S. Blood pressure changes during ketamine infusion for the treatment of depression. General Hospital Psychiatry 2024, 90: 62-67. PMID: 38991311, DOI: 10.1016/j.genhosppsych.2024.07.001.Peer-Reviewed Original ResearchKetamine infusionBlood pressure changesBlood pressureRetrospective chart review of patientsChart review of patientsMedical history of hypertensionRetrospective chart reviewHistory of hypertensionSignificant blood pressureDiastolic blood pressureTreatment of depressionSevere hypertensionPatient demographicsHypertensive patientsInfusion sessionsMedical historyHypertensive eventsInfusionPatientsKetamineBP surgeCardiovascular monitoringBloodHypertensionPressure changesKetamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
Jha M, Wilkinson S, Krishnan K, Collins K, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew S, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression. JAMA Network Open 2024, 7: e2417786. PMID: 38916891, PMCID: PMC11200139, DOI: 10.1001/jamanetworkopen.2024.17786.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionQIDS-SR16 scoresElectroconvulsive therapy groupElectroconvulsive therapyQIDS-SR16Measure of premorbid intelligencePosttraumatic stress disorder diagnosisTrial of electroconvulsive therapyNonpsychotic depressive episodeImpaired memory recallAssociated with differential improvementStress disorder diagnosisIntravenous ketamineEnd-of-treatment visitInfusion of ketamineMADRS scorePremorbid intelligenceResistant depressionDepressive episodeMeasures mixed-effects modelsFalse discovery rate adjustmentDisorder diagnosisMemory recallSevere depressionDifferential improvementThe Rapidly Shifting Ketamine Landscape in the US
Wilkinson S, Palamar J, Sanacora G. The Rapidly Shifting Ketamine Landscape in the US. JAMA Psychiatry 2024, 81: 221-222. PMID: 38170542, DOI: 10.1001/jamapsychiatry.2023.4945.Peer-Reviewed Original Research
2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original ResearchPsychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.Peer-Reviewed Original ResearchPsychiatric disordersLysergic acid diethylamideClinical trialsUS Clinical Trials RegistryClinical Trials RegistryPotential therapeutic effectsTrials RegistryTherapeutic effectPotential therapyTherapeutic agentsN-dimethyltryptamineAcid diethylamideLargest causePsychedelic compoundsDisordersPsychotherapeutic approachesSafety concernsTrialsPotential interactive effectsCutting-edge reviewPsychedelic substancesRegistryTherapyCognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyMajor depressionSuicidal ideationRelapse preventionBehavioral therapyStudy protocolHigh riskClinical trial study protocolLong-term treatment approachKey secondary outcomesTrial study protocolHigh relapse rateHigh-risk populationSignificant suicidal ideationHospital dischargeSecondary outcomesPrimary outcomeRelapse rateFeasibility trialEsketamineTreatment approachesPatientsSuicide attemptsTherapySupplemental indicationsEfficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Castro M, Wilkinson S, Al Jurdi R, Petrillo M, Zaki N, Borentain S, Fu D, Turkoz I, Sun L, Brown B, Cabrera P. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS Drugs 2023, 37: 715-723. PMID: 37558912, PMCID: PMC10439056, DOI: 10.1007/s40263-023-01026-3.Peer-Reviewed Original ResearchConceptsEsketamine nasal spraySUSTAIN 1Nasal spraySecond inductionMaintenance treatmentMADRS response ratesTreatment-emergent AEsDepression rating scoresNew safety signalsTreatment-resistant depressionTime of relapseLong-term treatmentLong-term trialsEligible patientsOral antidepressantsRemission rateStable remissionSubgroup analysisChronic illnessSafety signalsInterim analysisDepressive symptomsPatientsResponse rateRemissionTrends in Illicit Ketamine Seizures in the US From 2017 to 2022
Palamar J, Wilkinson S, Carr T, Rutherford C, Cottler L. Trends in Illicit Ketamine Seizures in the US From 2017 to 2022. JAMA Psychiatry 2023, 80: 750-751. PMID: 37223891, PMCID: PMC10209822, DOI: 10.1001/jamapsychiatry.2023.1423.Peer-Reviewed Original ResearchKetamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchConceptsTreatment-resistant major depressionPatient-reported qualityElectroconvulsive therapyMajor depressionECT groupKetamine groupTreatment phaseMusculoskeletal adverse effectsSubanesthetic intravenous ketamineWeeks of treatmentInitial treatment phaseIntravenous ketamineSecondary outcomesPrimary outcomeNoninferiority marginTrial groupECT clinicsNoninferiority trialPatientsComparative effectivenessKetamineClinical sitesAdverse effectsDepressionThree timesLong-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 2023, 48: 1225-1233. PMID: 37173512, PMCID: PMC10267177, DOI: 10.1038/s41386-023-01577-5.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionEsketamine treatmentMontgomery-Åsberg Depression Rating Scale (MADRS) total scoreCommon treatment-emergent adverse eventsLong-term extension studyTreatment-emergent adverse eventsEsketamine nasal sprayMean cumulative durationLong-term tolerabilityNew safety signalsHealth-related qualityMaintenance of responseLong-term treatmentMajor depressive disorderLong-term safetyPhase 3Scale total scoreMaintenance phaseOral antidepressantsData cutoffAdverse eventsMaintenance treatmentSustained efficacyEligible participantsDepression ratingsPharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis
Wilkinson S, Diaz D, Rupp Z, Kidambi A, Ramirez K, Flores J, Avila‐Quintero V, Rhee T, Olfson M, Bloch M. Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis. FOCUS The Journal Of Lifelong Learning In Psychiatry 2023, 21: 197-208. PMID: 37201149, PMCID: PMC10172559, DOI: 10.1176/appi.focus.23021006.Peer-Reviewed Original ResearchOdds of suicidePlacebo/Suicide riskPsychotic disordersBipolar disorderSuicide deathsMeta-analyzed associationsNon-clozapine antipsychoticsMagnetic seizure therapySomatic interventionsVagus nerve stimulationNewcastle-Ottawa ScaleAntiepileptic mood stabilizersTranscranial magnetic stimulationCertain clinical contextsDirect current stimulationEffects of pharmacologicPublic health crisisElectroconvulsive therapySeizure therapyNerve stimulationMood stabilizersStudy qualityProtective effectMagnetic stimulationPredictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray
Turkoz I, Nelson J, Wilkinson S, Borentain S, Macaluso M, Trivedi M, Williamson D, Sheehan J, Salvadore G, Singh J, Daly E. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Research 2023, 323: 115165. PMID: 37019044, DOI: 10.1016/j.psychres.2023.115165.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionEsketamine nasal sprayNasal sprayDay 28Day 8Clinical Global Impression-Severity scoreCGI-S scoresCurrent depressive episodePredictors of responsePlacebo nasal sprayIdentification of predictorsOral antidepressantsBaseline patientAcute trialPooled analysisDepressive episodeRemissionPsychiatric characteristicsPatientsSignificant anxietyYounger ageTreatment assignmentPotential predictorsPhase 3PredictorsThe Role of Psychotherapy in the Management of Treatment-Resistant Depression
Rogan T, Wilkinson S. The Role of Psychotherapy in the Management of Treatment-Resistant Depression. Psychiatric Clinics Of North America 2023, 46: 349-358. PMID: 37149349, DOI: 10.1016/j.psc.2023.02.006.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionRole of psychotherapySomatic therapiesLong-term outcomesPositive therapeutic benefitsPsychotherapy modalitiesRandomized trialsMood disordersTherapeutic benefitNeural plasticityTherapyMore trialsForms of psychotherapyTrialsDepressionLess evidenceModalitiesPsychotherapy approachesPsychotherapyPotential combinationsEffects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study.
Wilkinson S, Sint K, Forester B, Rhee T. Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36700843, DOI: 10.4088/jcp.22m14583.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyFunctional outcomeComorbid depressionPrincipal psychiatric diagnosisRandomized clinical trialsECT cohortECT patientsComparable cohortsSafe treatmentClinical trialsMedicare patientsCurrent treatmentFunctional declineLimited efficacyPropensity score methodsPsychiatric disordersSummary scoresPsychiatric diagnosisLarger sample sizeMultivariate analysisPsychological symptomsDementiaPatientsOlder adultsCohortLong-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression – final results of the SUSTAIN-3 study
Young A, Zaki N, Chen N, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Lacerda A, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression – final results of the SUSTAIN-3 study. Neuroscience Applied 2023, 2: 102450. DOI: 10.1016/j.nsa.2023.102450.Peer-Reviewed Original Research
2022
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry 2022, 79: 1162-1172. PMID: 36260324, PMCID: PMC9582972, DOI: 10.1001/jamapsychiatry.2022.3352.Peer-Reviewed Original ResearchConceptsStandardized mean differenceMajor depressive episodeSerious adverse eventsElectroconvulsive therapyAdverse eventsDepressive episodeClinical trialsDepression severityEfficacy outcomesSystematic reviewUnique adverse effect profileMeta-analyses (PRISMA) reporting guidelinesSafety of ketamineAdverse effect profileData extractionEuropean clinical trialsDiagnosis of depressionModerate methodological qualityMedical Subject Headings termsPreferred Reporting ItemsCognition/memoryRandom-effects modelSubject Headings termsAcute phaseEffect profileKetamine in the Real World: Where Do We Go From Here?
Wilkinson ST. Ketamine in the Real World: Where Do We Go From Here? The Journal Of Clinical Psychiatry 2022, 83 PMID: 36112579, DOI: 10.4088/JCP.22com14648.Peer-Reviewed Original ResearchInternational pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Molecular Psychiatry 2022, 27: 5096-5112. PMID: 36071111, PMCID: PMC9763119, DOI: 10.1038/s41380-022-01757-7.Peer-Reviewed Original ResearchConceptsMontgomery-Åsberg Depression Rating ScaleIndividual patient-level dataRating ScalePatient-level featuresDepression Rating ScaleHamilton Rating ScalePatient-level dataPrecision medicine approachRelevant psychiatric diagnosisEligible trialsIntravenous ketamineAntidepressant medicationStudy entryKetamine infusionPrior medicationAntidepressant propertiesKetamine effectsControl armClinical moderatorsTreatment decisionsTreatment resistanceStudy-level moderatorsDepressive symptomsPersonalized prescriptionDepression severityAt-home ketamine; still a lot to learn
Wilkinson ST, Sanacora G. At-home ketamine; still a lot to learn. Journal Of Affective Disorders 2022, 318: 150-151. PMID: 36067887, DOI: 10.1016/j.jad.2022.08.090.Peer-Reviewed Original Research